Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Expands By 19.7%

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) saw a large growth in short interest in February. As of February 27th, there was short interest totaling 4,210,945 shares, a growth of 19.7% from the February 12th total of 3,518,354 shares. Based on an average daily volume of 1,104,191 shares, the short-interest ratio is presently 3.8 days. Currently, 6.8% of the shares of the stock are sold short. Currently, 6.8% of the shares of the stock are sold short. Based on an average daily volume of 1,104,191 shares, the short-interest ratio is presently 3.8 days.

Analyst Ratings Changes

A number of research firms have commented on FULC. Bank of America boosted their price target on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. JPMorgan Chase & Co. initiated coverage on Fulcrum Therapeutics in a research report on Monday, January 12th. They set an “overweight” rating and a $20.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada boosted their price objective on Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Monday, December 8th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.00.

Insider Buying and Selling at Fulcrum Therapeutics

In related news, Director Robert J. Gould sold 15,000 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the sale, the director owned 469,864 shares in the company, valued at $5,577,285.68. This trade represents a 3.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 7.00% of the company’s stock.

Institutional Trading of Fulcrum Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Fulcrum Therapeutics during the 4th quarter valued at about $30,000. Quarry LP acquired a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $35,000. Meeder Asset Management Inc. acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $39,000. Russell Investments Group Ltd. raised its stake in shares of Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after buying an additional 9,092 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in Fulcrum Therapeutics by 108.3% in the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Price Performance

FULC stock opened at $7.30 on Wednesday. The company has a 50 day moving average price of $9.71 and a 200 day moving average price of $9.63. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $15.74. The stock has a market capitalization of $486.45 million, a PE ratio of -6.32 and a beta of 3.23.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). As a group, equities analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.